Colchicine has a number of effects that suggest it may be useful in the treatment of COVID-19. Myeloid cells are a major source of dysregulated inflammation in COVID-19. The hyperactivation of the NLRP3 inflammasome and the subsequent cytokine storm take place precisely inside them and can lead to multiorgan damage and death. NLRP3 inflammasome inhibition has been assessed at micromolar colchicine concentrations which cannot be achieved in serum. However, colchicine has remarkable ability to accumulate intensively in leukocytes, where the cytokine storm is generated. Over 50 observational studies and randomized clinical trials, small randomized non-controlled trials and retrospective cohort studies were initiated to test its healing effect in vivo, leading to conflicting, rather disappointing results. WHO gives ”Strong recommendation against” the use of colchicine for COVID-19 treatment. This is because low doses of colchicine are always used, where the concentrations required to inhibit the NLRP3 inflammasome in leukocytes cannot be reached. Considering this, from March 2020 we started the administration of higher doses of colchicine. Our assumption was that safe increase in colchicine doses to reach micromolar concentrations in leukocytes will result in NLRP3 inflammasome/cytokine storm inhibition. We demonstrated that in 785 inpatients treated with increasing doses of colchicine, mortality fell between 2 and 7 times. Our data, including also a large number of COVID-19 outpatients, showed that nearly 100% of the patients treated with this therapeutic regimen escaped hospitalization. In addition, post-covid symptoms in those treated with colchicine were significantly less. As a large number of viruses can overactivate the NLRP3 inflammasome (like seasonal influenza), we are convinced that higher colchicine doses would be useful in these cases as well.

Background: Inflammatory plays critical role in myocardial infarction as a critical process in the development of heart failure, involving the development of cardiac fibrosis. Colchicine is a well-established anti-inflammatory drug, but its scientific application in controlling post-acute myocardial infarction remodelling processes has not been established. IL-10, a key cytokine in modulating inflammatory responses, underscoring its potential as a crucial therapeutic target of colchicine. Objectives: To explore the protective role of IL-10 modulated by colchicine in myocardial healing and repair following AMI, particularly cardiac fibrosis. Materials and Methods: The predicted protein of Colchicine was assessed using WAY2DRUG PASS as probability active value. Proteins associated with Colchicine, cardiac fibrosis and acute myocardial infarction were analysed with DisGeNET and Open Target databases. Analysis and visualization of protein-protein interactions were conducted using STRING and Cytoscape. A 3T3 cell line treated with CoCl2 was used to mimic hypoxic. HIF-1α and IL-10 expression were measured by flow cytometry and analysed using a one-way ANOVA test. This observational clinical trial examined acute myocardial infarction patients undergoing immediate and delayed primary percutaneous coronary interventions. Subjects were randomized into control groups receiving placebo and intervention groups treated with Colchicine. Assessments occurred at 24 hours and five days after the intervention. IL-10 expression in the clinical trial was measured by ELISA assay and analysed using a T-test. Results: Colchicine demonstrates promising bioactivity in treating acute myocardial infarction, with notable probability active values as a tubulin antagonist (0.744), beta-tubulin antagonist (0.673), and NOS2 inhibitor (0.529). Its primary action targets IL-10, with protein-protein interactions analysis indicating interactions between IL-10 and key inflammatory mediators—IL-1β, IFN-γ, CCL2, TNF, and TGF-β1—during acute myocardial infarction and cardiac fibrosis. Hypoxic conditions in the CoCl2-induced 3T3 cell model show significantly elevated HIF-1α compared to controls (p<0.0001). Acute myocardial infarction patients were predominantly from high-risk populations, with notable smoking prevalence in the early Colchicine group (72%). Hypertension prevalence was significantly different, with 67.31% in the late Colchicine group compared to 38% in the early Colchicine and 39.80% in the early placebo groups. Both early and late Colchicine groups exhibited a higher prevalence of diabetes mellitus. Colchicine use, either early or late, did not significantly alter major adverse cardiovascular events incidence compared to placebo (p>0.05). However, Colchicine significantly increased IL-10 expression in CoCl2-treated cells (p<0.0001) and in acute myocardial infarction patients within five days (p<0.05). Conclusions: Colchicine may bolster the anti-inflammatory response post-myocardial infarction by activating IL-10 pathways in fibroblasts and in clinical settings, potentially reducing major adverse cardiovascular events. Further investigation into broader aspects of this pathway, particularly in cardiac fibroblasts, is required.

. Colchicine (C22H25NO6) is a substance used for inducing mutations in order to regulate important agronomic traits. The objective of this study was to investigate the effect of different concentrations (0.0, 0.04, 0.06, 0.08 and 0.1%) and treatment time (6, 12 and 24 h) of colchicine on agronomic traits of proso millet (Panicum miliaceum L.) and to assess the genetic diversity of M2 generations using inter simple sequence repeat markers (ISSR). The experiment was conducted in 2021 for the M1-generation and in 2022 for the M2-generation, from May to September. The percentage of the field germination was decreased with the increasing colchicine concentration and exposure duration. The chlorophyll-defective M1-M2 plants were obtained using various concentrations and exposure periods of colchicine. The highest amount of mutational modifications was attained at 0.08-0.1% concentrations colchicine. A total of 248 plant families with chlorophyll-defective mutations based on the research results were selected from 2214 families. The growing season of M1- and M2 plants were diminished under higher colchicine concentration (0.08-0.1%) combined with soaking time. Thus, the highest indicator of growing season (84 days) was observed at six h treatment time for PI 289324, while the fewest (78 days) was recorded at 12 and 24 h. The possibility of obtaining morphological mutations using colchicine has been confirmed. The ISSR primers amplified a total of 1333 fragments, 1281 bands were found to be polymorphic and 52 bands monomorphic. The percentage of polymorphism varied from 80 to 100 % with an average of 96.11%. Our results showed that most of the bands were found at 0.08% colchicine concentration. These positive variations are a great opportunity to use colchicine as a tool for improving agronomic traits in plant breeding.

Legumes play a significant role in the alleviation of food insecurity, maintaining soil fertility and achieving sustainable crop production under adverse environmental conditions. The increased demand in legume production contemplates that attention on the genetic improvement of these crops through various means such as genetic engineering and mutation breeding should take a centre stage in global agriculture. Therefore, this paper provides succinct analysis of currently available literature on morphological and physiological traits in polyploidised leguminous plants to counter the adverse effects of drought stress. The effects of colchicine on various morphological and physiological traits of polyploidised legumes compared to their diploid counterparts were examined. Numerous reports revealed variations in these traits such as improved root and shoot growth, plant biomass, chloroplastidic content, protein, RNA and DNA. The differences observed were also associated with the strong relationship between plant ploidy-induction and colchicine application. Furthermore, the analysis indicated that polyploidisation remains dose-dependent, and may be achievable at a shorter space of time as this antimitotic chemical interferes with chromosome separations in somatic plant cells. The efficiency of this process also depends on the advancement of treatment conditions (in vitro, in vivo or ex vitro) and successful regeneration of polyploidised plants for adaptation under drought stress conditions. As such, the improvement in metabolite profile and other essential growth characteristics serves as a clear indication that induced polyploidy needs to be further explored to confer resilience to environmental stress, and improve crop yield under drought stress conditions in leguminous plants.

Although there are numerous available immunomodulators, those of natural origin would be preferable based on their safety profile and effectiveness. The research and clinical interest in immunomodulators have increased in the last decades, especially in the immunomodulatory properties of plant-based therapies. Innovative technologies and extensive study on immunomodulatory natural products, botanicals, extracts, and active moieties with immunomodulatory potential could provide us with valuable entities to develop as novel immunomodulatory medicines to enhance current chemotherapies. This review focuses on plant-based immunomodulatory drugs that are currently in clinical studies. However, further studies in this area are of utmost importance to obtain complete information about the positive effects of medicinal plants and their chemical components and molecules as an alternative to combatting various diseases and/or prevention.

Polyploidy induction is recognized as one of the major evolutionary processes presenting remark-able morphological, physiological, and genetic variations in plants. Soybean (Glycine max L.), also known as soja bean or soya bean, is an annual leguminous crop of the pea family (Fabaceae) that shares a paleopolypoidy history, dating back to approximately 56.5 million years ago with other leguminous crops such as cowpea and other Glycine specific polyploids. This crop has been documented as one of the polyploid complex species among legumes whose gene evolution and result-ant adaptive growth characteristics, following induced polyploidization has not been fully explored. Furthermore, there are no successfully established in vivo or in vitro based polyploidy in-duction protocols that have been reported so far, particularly, with the intention to develop mutant plants showing strong resistance to abiotic salinity stress. This review, therefore, describes the role of synthetic polyploid plant production in soybean for the mitigation against high soil salt stress levels, and how this evolving approach could be used to further enhance nutritional, pharmaceutical and economic industrial value of soybeans, including addressing challenges involved during the polyploidization process.

Bangladesh faces significant wheat grain deficiency compared to its demand due to the lengthy process (10-12 years) required to release a variety through a conventional breeding approach. Traditional breeding methods involve several years of various types of crosses between male and female parents and/or progenies, along with recurrent selection-crossing to obtain a homozygous line (F₁ to F₆ generations) with desired traits within almost 10 years. The double haploid (DH) method is also a time-saving, easier, and more reliable technique to achieve the desired traits in homozygous lines within 2-3 years. DH lines were produced by crossing two F₁ hybrids of spring wheat with maize. 0.1% solution of colchicine was applied to produce DH of F₂ progeny of wheat in the study. 80.8% (340) of the 421 pollinated florets from the two F₁ wheat hybrids were produced as green parthenocarpic caryopses (GPCs) (F₂). 35 of the 70 rescued embryos (or 20.6% of the GPCs) germinated. The germinated embryos regenerated 10 haploid green plants (14.3% of total embryos). After being applied colchicine, 8 of the regenerated haploid (H₁) plants made it. Out of the 8 plants that made it through, only one developed homozygous double haploid seed (DH₁ seed). These seeds were multiplied to produce DH₂, used in the preliminary yield in the next year. The results demonstrated the potential of this method to produce a homozygous line within a short period (2-3 years) by doubling the haploid line generated through pollination of spring bread wheat F₁ with maize.

The role of inflammation in the pathophysiology of acute myocardial infarction (AMI) is well established. Recognizing inflammation's pivotal role in AMI, this manuscript systematically traces historical studies, spanning from early attempts to the present landscape. Several anti-inflammatory trials targeting inflammation in post-AMI have been performed. The review includes key trials, examining their designs, patient demographics, and primary outcomes. Efficacy and challenges are analyzed, shedding light on the translational implications of trial outcomes. The article also discusses emerging trends, ongoing research, and potential future directions in the field. Practical applications and implications for clinical practice are considered, providing a holistic view of the evolving landscape of anti-inflammatory interventions in the context of AMI.